Ascendis Pharma A/SASND
ASignal's systematic analysis rates ASND as Bullish.
Reflects the latest available analysis · analyzed Sep 2, 2026
The case on ASND
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong revenue growth (114.7% YoY)
- High gross and operating margins (91.3%, 64.98%)
- Positive free cash flow and strong cash position ($812.26M cash, low debt)
- Debt-to-equity ratio of 0.31x indicates solid financial health
- MACD above signal line with expanding histogram suggests strengthening momentum
- Price above SMA20 and SMA50, indicating uptrend
- RSI at 68.34, approaching overbought territory
- Price trading above upper Bollinger Band, suggesting potential overextension
- Forward P/E of 28.09x and high EV/EBITDA of 63.50x indicate rich valuation
- PEG ratio not available, limiting growth-adjusted valuation analysis
- No Reddit mentions, indicating limited retail sentiment or visibility
See the full verdict on ASND
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes ASND
Most investors never get a second opinion, let alone several. ASignal runs ASND past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.